ReviewCureus2026
Perioperative Management of Immune Thrombocytopenic Purpura in Cardiac Surgery: A Systematic Review of the Literature in Urgent and Elective Settings.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perioperative management of immune thrombocytopenic purpura (ITP) in cardiac surgery represents a rare yet formidable clinical challenge driven by immune-mediated platelet dysfunction, obligatory systemic anticoagulation, and the profound hemostatic derangements induced by cardiopulmonary bypass. We systematically synthesized the available evidence on perioperative strategies and outcomes in adults with ITP undergoing cardiac surgery in elective and urgent or emergent settings by reviewing PubMed/MEDLINE, Embase, Scopus, Web of Science, Cochrane CENTRAL, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform from inception through August 26, 2025. Nineteen studies comprising approximately 74 patients, predominantly with severe thrombocytopenia, were identified, including three observational cohorts and sixteen case reports or series. Reported management approaches centered on rapid immunomodulation with intravenous immunoglobulin and/or corticosteroids, selective adjunctive platelet transfusion, antifibrinolytic therapy, thrombopoietin receptor agonists in selected cases, and carefully monitored cardiopulmonary bypass anticoagulation, most commonly using unfractionated heparin with activated clotting time guidance; bivalirudin was described in isolated reports. Across studies, perioperative bleeding occurred in approximately 32% of patients, platelet transfusion in 45%, reoperation for bleeding in 8%, thrombotic complications in 6%, and perioperative mortality in 7%, with consistently inferior outcomes observed in urgent and emergent procedures. Although the evidence base remains largely case-derived and heterogeneous, these data support a coherent multimodal perioperative strategy integrating rapid platelet-directed immunotherapy, patient blood management-guided hemostasis, antifibrinolytic use, and vigilant anticoagulation, while underscoring the urgent need for prospective, multicenter registries with harmonized outcome definitions to inform standardized, evidence-based perioperative pathways for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.